Abstract
The paper highlights the principal items of use of decongestants in the treatment of rhinosinusitis in children. It analyzes the advantages and disadvantages of all classes of decongestants and their role in the pathogenetic therapy of rhinosinusitis. The role of complex vasoconstrictors including excipients (certain components of essential oils) is defined, by using Lasolvan®Rhino as an example. The efficient and timely therapy of acute rhinitis in children can considerably reduce the frequency of complications and improve a child’s health, helping restore normal eating and sleep. Since the earliest treatment is of the greatest importance in the therapy of acute rhinosinusitis, emphasis is placed on decongestants within the first days of the disease. The decongestant Lasolvan®Rhino (Boehringer Ingelheim) fully meets the goals of treatment for acute rhinosinusitis in children over 6 years of age as an effective, reliable, and safe agent, as evidenced by clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
